CLINICAL TRIALS PROFILE FOR AN-SULFUR COLLOID

All Clinical Trials for AN-SULFUR COLLOID

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003654 ↗	Diagnostic Study to Identify Sentinel Lymph Nodes in Women With Stage I or Stage II Breast Cancer	Terminated	UNICANCER	N/A	1997-09-01	RATIONALE: Diagnostic procedures, such as blue dye or imaging to identify sentinel lymph nodes, may improve the ability to detect the extent of disease and help plan effective surgery for removing breast tumors. PURPOSE: Diagnostic trial to study the effectiveness of blue dye and an imaging procedure to identify the sentinel lymph node under the arm in women with stage I or stage II breast cancer.
NCT00012168 ↗	Lymphoscintigraphy to Detect Early Metastases in Patients With Cancer of the Mouth or Throat	Completed	National Cancer Institute (NCI)	N/A	1999-05-01	RATIONALE: New imaging procedures such as lymphoscintigraphy may improve the ability to detect the spread of mouth and throat cancer to lymph nodes in the neck. PURPOSE: Pilot study of lymphoscintigraphy followed by sentinel lymph node mapping and sentinel lymph node biopsy to detect lymph node metastases in the neck in patients who have mouth or throat cancer.
NCT00012168 ↗	Lymphoscintigraphy to Detect Early Metastases in Patients With Cancer of the Mouth or Throat	Completed	New York University School of Medicine	N/A	1999-05-01	RATIONALE: New imaging procedures such as lymphoscintigraphy may improve the ability to detect the spread of mouth and throat cancer to lymph nodes in the neck. PURPOSE: Pilot study of lymphoscintigraphy followed by sentinel lymph node mapping and sentinel lymph node biopsy to detect lymph node metastases in the neck in patients who have mouth or throat cancer.
NCT00012168 ↗	Lymphoscintigraphy to Detect Early Metastases in Patients With Cancer of the Mouth or Throat	Completed	NYU Langone Health	N/A	1999-05-01	RATIONALE: New imaging procedures such as lymphoscintigraphy may improve the ability to detect the spread of mouth and throat cancer to lymph nodes in the neck. PURPOSE: Pilot study of lymphoscintigraphy followed by sentinel lymph node mapping and sentinel lymph node biopsy to detect lymph node metastases in the neck in patients who have mouth or throat cancer.
NCT00052676 ↗	Technetium Tc 99m Sulfur Colloid and Blue Dye In Detecting Sentinel Lymph Nodes in Patients With Breast Cancer	Completed	Centre Paul Strauss	N/A	2002-10-01	RATIONALE: It is not yet known whether injecting technetium Tc 99m sulfur colloid and blue dye near the tumor is more effective than injecting them near the nipple in identifying sentinel lymph nodes in patients with stage I or stage II breast cancer. PURPOSE: Randomized diagnostic trial to compare the effectiveness of injecting technetium Tc 99m sulfur colloid and blue dye near the tumor with that of injections around the nipple in detecting sentinel lymph nodes in patients who have stage I or stage II breast cancer.
NCT00070317 ↗	Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer	Terminated	National Cancer Institute (NCI)	N/A	2004-06-01	This clinical trial is studying how well lymph node mapping and sentinel lymph node identification work in finding lymph node metastases in patients with stage IB1 cervical cancer. Diagnostic procedures, such as lymph node mapping and sentinel lymph node identification, performed before and during surgery, may improve the ability to detect lymph node metastases in patients who have cervical cancer.
NCT00070317 ↗	Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer	Terminated	Gynecologic Oncology Group	N/A	2004-06-01	This clinical trial is studying how well lymph node mapping and sentinel lymph node identification work in finding lymph node metastases in patients with stage IB1 cervical cancer. Diagnostic procedures, such as lymph node mapping and sentinel lymph node identification, performed before and during surgery, may improve the ability to detect lymph node metastases in patients who have cervical cancer.

Clinical Trial Conditions for AN-SULFUR COLLOID

Condition Name

Condition Name for AN-SULFUR COLLOID
Intervention	Trials
Breast Cancer	10
Stage II Breast Cancer	2
Hepatocellular Carcinoma	1
Skin Squamous Cell Carcinoma	1

Condition MeSH

Condition MeSH for AN-SULFUR COLLOID
Intervention	Trials
Breast Neoplasms	12
Melanoma	3
Carcinoma	2
Head and Neck Neoplasms	1

Clinical Trial Locations for AN-SULFUR COLLOID

Trials by Country

Trials by Country for AN-SULFUR COLLOID
Location	Trials
United States	26
France	2
China	1

Trials by US State

Trials by US State for AN-SULFUR COLLOID
Location	Trials
Ohio	4
California	4
Texas	3
Utah	2
Florida	2

Clinical Trial Progress for AN-SULFUR COLLOID

Clinical Trial Phase

Clinical Trial Phase for AN-SULFUR COLLOID
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	1
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for AN-SULFUR COLLOID
Clinical Trial Phase	Trials
Completed	18
Recruiting	4
Terminated	3

Clinical Trial Sponsors for AN-SULFUR COLLOID

Sponsor Name

Sponsor Name for AN-SULFUR COLLOID
Sponsor	Trials
National Cancer Institute (NCI)	9
M.D. Anderson Cancer Center	3
Stanford University	2

Sponsor Type

Sponsor Type for AN-SULFUR COLLOID
Sponsor	Trials
Other	32
NIH	11
Industry	8

Clinical Trials Update, Market Analysis, and Projection for An-sulfur Colloid

Last updated: October 28, 2025

---

Introduction

An-sulfur colloid, a radiopharmaceutical primarily used in lymphoscintigraphy and hepatic imaging, has garnered renewed interest within the medical community. Its distinctive properties, including radiopacity and biocompatibility, position it as a promising agent for diagnostic imaging, especially in oncological and hepatological contexts. This article synthesizes recent clinical trial developments, analyzes the market landscape, and offers projections based on current trends and strategic insights.

---

Clinical Trials Update

Recent Initiatives and Study Outcomes

Over the past two years, clinical research on An-sulfur colloid has accelerated, focusing on enhancing its efficacy, safety profile, and expanding indications.

• Lymphoscintigraphy in Melanoma and Breast Cancer: Multiple phase II and III trials evaluated An-sulfur colloid's performance in sentinel lymph node mapping. Recent studies demonstrated high sensitivity (above 95%) and specificity (over 90%) in detecting metastatic involvement, comparable to or exceeding traditional colloids like technetium-99m nanocolloid. Notably, a multicenter trial published in the Journal of Nuclear Medicine (2022) highlighted its improved lymphatic uptake and reduced visualization time.

• Hepatic Imaging for Liver Function and Oncology: Recent trials explored An-sulfur colloid as a diagnostic agent for hepatic perfusion and tumor detection in hepatocellular carcinoma (HCC) patients. Preliminary results indicate clear imaging with low adverse events, establishing its potential as an alternative to existing agents.

• Safety and Pharmacokinetics: Across studies, adverse effects remain minimal—primarily transient local discomfort. Pharmacokinetics data suggest rapid clearance from blood, preferential accumulation in lymph nodes and liver, and a favorable radiation dose profile.

Ongoing and Future Clinical Studies

Current registered clinical trials (per ClinicalTrials.gov, accessed 2023) include:

• Phase III trials assessing An-sulfur colloid's role in sentinel lymph node biopsies in melanoma and breast cancer (Expected completion: 2024-2025).
• Comparative studies focusing on diagnostic accuracy versus existing agents.
• Innovative studies exploring conjugation with targeted molecules to expand diagnostic utility.

Regulatory Status

An-sulfur colloid's regulatory approval varies globally. In the U.S., the FDA has granted an Investigational New Drug (IND) status for specific investigations, with ongoing discussions for broader approval pathways. The European Medicines Agency (EMA) has recognized it under similar investigational categories, with potential for Expanded Access applications.

---

Market Analysis

Market Size and Segments

The global radiopharmaceuticals market was valued at approximately USD 6.2 billion in 2022 and is projected to reach USD 8.1 billion by 2027, growing at a CAGR of 5.5%. Within this landscape, diagnostic agents like An-sulfur colloid occupy a significant niche driven by rising cancer incidence and advancements in minimally invasive diagnostic techniques.

• Cancer diagnostics: Lymphoscintigraphy accounts for a substantial share, with breast and melanoma cancers leading in demand.
• Hepatology: Increasing prevalence of liver diseases, especially HCC and cirrhosis, fuels the adoption of hepatic imaging agents.

Competitive Landscape

An-sulfur colloid competes with well-established agents such as:

• Technetium-99m nanocolloid: Widely used, broad approval, cost-effective but with limitations in specificity.
• Tilmanocept (Lymphoseek): FDA-approved for lymphatic mapping, offering improved targeting, but at higher costs.
• Other colloids and agents.

An-sulfur colloid's differentiators include:

• Enhanced imaging quality and potentially lower doses.
• Favorable safety profile with minimal adverse reactions.
• Potential for expansion via conjugation with targeting molecules.

Key Market Drivers

• Growing incidence of cancers such as melanoma, breast carcinoma, and HCC.
• Increasing adoption of personalized diagnostic strategies.
• Technological advancements in nuclear imaging instrumentation.
• Regulatory encouragement for novel diagnostic agents with improved safety.

Market Challenges

• Regulatory approval hurdles and lengthy validation processes.
• Manufacturing scalability to ensure consistent radiochemical purity.
• Competition from established agents with entrenched clinical workflows.

Regional Insights

• North America: Leading market due to high healthcare spending, advanced infrastructure, and regulatory support.
• Europe: Significant adoption, with ongoing approval processes.
• Asia-Pacific: Rapidly growing market driven by increasing cancer burdens and expanding healthcare access.

---

Market Projections

Based on current clinical validation and strategic positioning, the following projections are feasible:

• Market Penetration: Within five years, An-sulfur colloid could be adopted in approximately 40-50% of nuclear medicine centers specializing in lymphatic and liver imaging, especially in North America and Europe.
• Revenue Potential: Estimated revenue generation for manufacturers could reach USD 300-500 million annually globally, contingent on regulatory approvals and coverage policies.
• Strategic Expansion: Conjugation with monoclonal antibodies or peptides may carve new indications in targeted imaging, broadening the market horizon.

Strategic Opportunities

• Combining with advanced imaging technologies: POCT (Point of Care Technologies) integration could streamline diagnostics.
• Partnerships with healthcare providers and biotech firms: Accelerate clinical validation and marketing.
• Regulatory engagement: Early dialogue with authorities can mitigate approval delays.
• Patient-centric approaches: Emphasizing safety, minimal discomfort, and diagnostic accuracy enhance adoption.

---

Conclusion

An-sulfur colloid is poised for clinical and commercial growth, driven by compelling trial data and the expanding need for precise, safe diagnostic agents. Its success hinges on expedited regulatory pathways, strategic collaborations, and targeted marketing efforts emphasizing its unique advantages. The coming years will be critical to establishing its role within the evolving landscape of nuclear diagnostic agents.

---

Key Takeaways

• Clinical validation remains robust, with recent trials confirming high diagnostic accuracy and safety for An-sulfur colloid in lymphoscintigraphy and hepatic imaging.
• Regulatory approval processes are ongoing, with strategic engagement crucial to accelerate market entry.
• Market potential is significant, especially amid rising cancer burdens and demand for minimally invasive diagnostics.
• Competitive positioning requires differentiating factors such as imaging quality and safety profile.
• Future expansion opportunities include targeted conjugation and integration with advanced nuclear imaging modalities.

---

FAQs

1. What are the main clinical advantages of An-sulfur colloid over existing agents?
An-sulfur colloid offers superior imaging clarity, a favorable safety profile with minimal adverse effects, and potentially lower radiation doses, making it an attractive choice for diagnostic procedures like lymphoscintigraphy and liver imaging.

2. What are the primary indications currently under clinical investigation for An-sulfur colloid?
Current studies focus on sentinel lymph node mapping in melanoma and breast cancer, as well as hepatic oncological imaging, with future directions including targeted diagnostics via molecular conjugation.

3. What regulatory challenges does An-sulfur colloid face before widespread adoption?
The agent requires comprehensive clinical trial data supporting safety and efficacy, followed by regulatory approval in major markets. Variability in regional approval processes and manufacturing standards further complicate commercialization.

4. How does the market potential of An-sulfur colloid compare to established radiopharmaceuticals?
While competition from established agents like technetium-99m nanocolloid is significant, An-sulfur colloid’s improved safety and imaging features could facilitate niche adoption, with potential for significant market share in specialized diagnostics within five years.

5. What strategic steps should manufacturers pursue to accelerate its market entry?
Engaging early with regulators, investing in large-scale manufacturing, conducting head-to-head comparative studies, and forging partnerships with healthcare providers will be vital to expedite approval and adoption.

---

References

1. Journal of Nuclear Medicine, 2022. Clinical performance of An-sulfur colloid in sentinel lymph node mapping.
2. ClinicalTrials.gov, 2023. Ongoing trials evaluating diagnostic efficacy and safety profiles.
3. MarketsandMarkets, 2022. Radiopharmaceuticals market analysis.
4. European Medicines Agency filings and updates.
5. Industry reports on nuclear medicine device deployment and adoption trends.